Literature DB >> 15951960

Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort.

Kelly-Anne Phillips1, Phyllis N Butow, Ailsa E Stewart, Jiun-Horng Chang, Prue C Weideman, Melanie A Price, Sue Anne McLachlan, Geoffrey J Lindeman, Michael J McKay, Michael L Friedlander, John L Hopper.   

Abstract

INTRODUCTION: Prospective collection of epidemiological, psychosocial and outcome data in large breast cancer family cohorts should provide less biased data than retrospective studies regarding penetrance of breast cancer and modifiers of genetic risk.
METHODS: The Kathleen Cuningham Foundation for Research into Breast Cancer (kConFab) recently commenced 3-yearly follow-up on over 750 families with multiple cases of breast cancer. Clinical follow-up was by mailed self-report questionnaire to all participants, while psychosocial follow-up was only of unaffected women and consisted of two components: a mailed questionnaire and an interview regarding stressful life events.
RESULTS: To date, 1928 of 2748 (70%) participants returned the clinical follow-up questionnaire (10% opted out, 16% were non-responders, and 4% were not contactable). Of the unaffected females who returned the clinical follow-up questionnaire, 91% participated in the psychosocial follow-up. In multivariate analyses, sex, personal cancer status, marital status, age and educational status were independent predictors of response to the clinical follow-up questionnaire, and number of female children, age, and family history of breast cancer were independent predictors of response to the psychosocial follow-up.
CONCLUSIONS: A first round of 3-yearly clinical and psychosocial follow-up using a mailed questionnaire was feasible in this cohort. High response rates were achieved by employing intensive tracing and reminder strategies. The predictors of response for the clinical and psychosocial follow-up components of this study should be considered in designing similar follow-up strategies for other family cancer cohorts.

Entities:  

Mesh:

Year:  2005        PMID: 15951960     DOI: 10.1007/s10689-004-6129-x

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  28 in total

1.  Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  Steven A Narod; Marie-Pierre Dubé; Jan Klijn; Jan Lubinski; Henry T Lynch; Parviz Ghadirian; Diane Provencher; Ketil Heimdal; Pal Moller; Mark Robson; Kenneth Offit; Claudine Isaacs; Barbara Weber; Eitan Friedman; Ruth Gershoni-Baruch; Gad Rennert; Barbara Pasini; Theresa Wagner; Mary Daly; Judy E Garber; Susan L Neuhausen; Peter Ainsworth; Hakan Olsson; Gareth Evans; Michael Osborne; Fergus Couch; William D Foulkes; Ellen Warner; Charmaine Kim-Sing; Olufunmilayo Olopade; Nadine Tung; Howard M Saal; Jeffrey Weitzel; Sofia Merajver; Marion Gauthier-Villars; Helena Jernstrom; Ping Sun; Jean-Sebastien Brunet
Journal:  J Natl Cancer Inst       Date:  2002-12-04       Impact factor: 13.506

Review 2.  Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation.

Authors:  Hester M Klaren; Laura J van't Veer; Flora E van Leeuwen; Matti A Rookus
Journal:  J Natl Cancer Inst       Date:  2003-07-02       Impact factor: 13.506

3.  Response rate to mailed epidemiologic questionnaires: a population-based randomized trial of variations in design and mailing routines.

Authors:  S Eaker; R Bergström; A Bergström; H O Adami; O Nyren
Journal:  Am J Epidemiol       Date:  1998-01-01       Impact factor: 4.897

4.  The Cooperative Familial Registry for Breast Cancer Studies: design and first year recruitment rates in Ontario.

Authors:  H J Sutherland; J Lacroix; J Knight; I L Andrulis; N F Boyd
Journal:  J Clin Epidemiol       Date:  2001-01       Impact factor: 6.437

5.  Evaluation of potential sources of bias in a genetic epidemiologic study of breast cancer.

Authors:  L M Seybolt; C Vachon; K Potter; W Zheng; L H Kushi; P G McGovern; T A Sellers
Journal:  Genet Epidemiol       Date:  1997       Impact factor: 2.135

6.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

7.  Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics.

Authors:  Clare L Scott; Mark A Jenkins; Melissa C Southey; Tracey A Davis; Jennifer A Leary; Douglas F Easton; Kelly-Anne Phillips; John L Hopper
Journal:  Hum Genet       Date:  2003-02-25       Impact factor: 4.132

8.  Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium.

Authors:  D F Easton; D T Bishop; D Ford; G P Crockford
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

9.  Survey non-response in the Netherlands: effects on prevalence estimates and associations.

Authors:  A Jeanne M Van Loon; Marja Tijhuis; H Susan J Picavet; Paul G Surtees; Johan Ormel
Journal:  Ann Epidemiol       Date:  2003-02       Impact factor: 3.797

10.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

View more
  27 in total

1.  Intuition versus cognition: a qualitative exploration of how women understand and manage their increased breast cancer risk.

Authors:  Louise Heiniger; Phyllis N Butow; Margaret Charles; Melanie A Price
Journal:  J Behav Med       Date:  2015-03-28

2.  Recreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult Women at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and Genetic Risk.

Authors:  Rebecca D Kehm; Jeanine M Genkinger; Robert J MacInnis; Esther M John; Kelly-Anne Phillips; Gillian S Dite; Roger L Milne; Nur Zeinomar; Yuyan Liao; Julia A Knight; Melissa C Southey; Wendy K Chung; Graham G Giles; Sue-Anne McLachlan; Kristen D Whitaker; Michael Friedlander; Prue C Weideman; Gord Glendon; Stephanie Nesci; kConFab Investigators; Irene L Andrulis; Saundra S Buys; Mary B Daly; John L Hopper; Mary Beth Terry
Journal:  Cancer Res       Date:  2019-10-02       Impact factor: 12.701

3.  Misconceptions about breast lumps and delayed medical presentation in urban breast cancer patients.

Authors:  Garth H Rauscher; Carol Estwing Ferrans; Karen Kaiser; Richard T Campbell; Elizabeth E Calhoun; Richard B Warnecke
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-03       Impact factor: 4.254

4.  Looking different, feeling different: women's reactions to risk-reducing breast and ovarian surgery.

Authors:  Nina Hallowell; Brandi Baylock; Louise Heiniger; Phyllis N Butow; Deepa Patel; Bettina Meiser; Christobel Saunders; Melanie A Price
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

5.  Facilitators and Challenges in Psychosocial Adaptation to Being at Increased Familial Risk of Breast Cancer.

Authors:  Louise Heiniger; Melanie A Price; Margaret Charles; Phyllis N Butow
Journal:  J Genet Couns       Date:  2015-03-05       Impact factor: 2.537

6.  Predictors of cancer worry in unaffected women from high risk breast cancer families: risk perception is not the primary issue.

Authors:  Melanie Anne Price; Phyllis Noami Butow; Sing Kai Lo; Judy Wilson
Journal:  J Genet Couns       Date:  2007-09-09       Impact factor: 2.537

7.  Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer.

Authors:  Bettina Meiser; Melanie A Price; Phyllis N Butow; Janan Karatas; Judy Wilson; Louise Heiniger; Brandi Baylock; Margaret Charles; Sue-Anne McLachlan; Kelly-Anne Phillips
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

8.  Long-term outcomes of risk-reducing surgery in unaffected women at increased familial risk of breast and/or ovarian cancer.

Authors:  Louise Heiniger; Phyllis N Butow; Joseph Coll; Tracey Bullen; Judy Wilson; Brandi Baylock; Bettina Meiser; Melanie A Price
Journal:  Fam Cancer       Date:  2015-03       Impact factor: 2.375

9.  Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium.

Authors:  Nadine Andrieu; David E Goldgar; Hongyan Li; Mary Beth Terry; Antonis C Antoniou; Kelly-Anne Phillips; Karin Kast; Thea M Mooij; Christoph Engel; Catherine Noguès; Dominique Stoppa-Lyonnet; Christine Lasset; Pascaline Berthet; Veronique Mari; Olivier Caron; Daniel Barrowdale; Debra Frost; Carole Brewer; D Gareth Evans; Louise Izatt; Lucy Side; Lisa Walker; Marc Tischkowitz; Mark T Rogers; Mary E Porteous; Katie Snape; Hanne E J Meijers-Heijboer; Johan J P Gille; Marinus J Blok; Nicoline Hoogerbrugge; Mary B Daly; Irene L Andrulis; Saundra S Buys; Esther M John; Sue-Anne McLachlan; Michael Friedlander; Yen Y Tan; Ana Osorio; Trinidad Caldes; Anna Jakubowska; Jacques Simard; Christian F Singer; Edith Olah; Marie Navratilova; Lenka Foretova; Anne-Marie Gerdes; Marie-José Roos-Blom; Brita Arver; Håkan Olsson; Rita K Schmutzler; John L Hopper; Roger L Milne; Douglas F Easton; Flora E Van Leeuwen; Matti A Rookus
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-12-02       Impact factor: 4.254

10.  Prostate screening uptake in Australian BRCA1 and BRCA2 carriers.

Authors:  Joanne M McKinley; Prue C Weideman; Mark A Jenkins; Michael L Friedlander; John L Hopper; Sue-Anne McLachlan; Geoffrey J Lindeman; Kelly-Anne Phillips
Journal:  Hered Cancer Clin Pract       Date:  2007-09-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.